Molecular pathogenesis of the myeloproliferative neoplasms
G Greenfield, MF McMullin, K Mills - Journal of Hematology & Oncology, 2021 - Springer
The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …
JAK/STAT signaling in hematological malignancies
W Vainchenker, SN Constantinescu - Oncogene, 2013 - nature.com
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …
central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane …
Janus kinases in immune cell signaling
K Ghoreschi, A Laurence, JJ O'Shea - Immunological reviews, 2009 - Wiley Online Library
The Janus family kinases (Jaks), Jak1, Jak2, Jak3, and Tyk2, form one subgroup of the non‐
receptor protein tyrosine kinases. They are involved in cell growth, survival, development …
receptor protein tyrosine kinases. They are involved in cell growth, survival, development …
New mutations and pathogenesis of myeloproliferative neoplasms
W Vainchenker, F Delhommeau… - Blood, The Journal …, 2011 - ashpublications.org
Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive
production of mature blood cells. In the majority of classic MPN—polycythemia vera …
production of mature blood cells. In the majority of classic MPN—polycythemia vera …
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET),
and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic …
and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic …
[HTML][HTML] SOCS proteins in development and disease
MC Trengove, AC Ward - American journal of clinical and …, 2013 - ncbi.nlm.nih.gov
Cytokine and growth factor signaling mediates essential roles in the differentiation,
proliferation, survival and function of a number of cell lineages. This is achieved via specific …
proliferation, survival and function of a number of cell lineages. This is achieved via specific …
Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal
AM Vannucchi, E Antonioli, P Guglielmelli, A Pardanani… - Leukemia, 2008 - nature.com
JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2
mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV) …
mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV) …
[HTML][HTML] Erythropoietin regulation of red blood cell production: From bench to bedside and back
SV Bhoopalan, LJ Huang, MJ Weiss - F1000Research, 2020 - ncbi.nlm.nih.gov
More than 50 years of efforts to identify the major cytokine responsible for red blood cell
(RBC) production (erythropoiesis) led to the identification of erythropoietin (EPO) in 1977 …
(RBC) production (erythropoiesis) led to the identification of erythropoietin (EPO) in 1977 …
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S Hart, KC Goh, V Novotny-Diermayr, CY Hu, H Hentze… - Leukemia, 2011 - nature.com
SB1518 is an innovative pyrimidine-based macrocycle that shows a unique kinase profile
with selective inhibition of Janus Kinase-2 (JAK2; IC 50= 23 and 19 n M for JAK2 WT and …
with selective inhibition of Janus Kinase-2 (JAK2; IC 50= 23 and 19 n M for JAK2 WT and …
Mining for JAK–STAT mutations in cancer
The Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway
mediates signaling by cytokines, which control survival, proliferation and differentiation of …
mediates signaling by cytokines, which control survival, proliferation and differentiation of …